VU0364739为一种具有选择性的PLD2抑制剂（IC50：22 nM），可降低癌细胞的增殖。

Phospholipase A2 (PLA2) catalyzes the hydrolysis of phospholipids at the sn-2 position leading to the production of lysophospholipids and free fatty acids. Calcium-dependent cytosolic PLA2 (cPLA2α) is a 85 kDa enzyme that plays a key role in the arachidonic cascade and the inflammatory response associated with this metabolic pathway. CAY10502 is a potent inhibitor of calcium-dependent cytosolic PLA2α (cPLA2α) with an IC50 value of 4.3 nM for the purified enzyme from human platelets. It inhibits arachidonic acid mobilization from A23187-stimulated or TPA-stimulated human platelets with IC50 values of 570 and 0.9 nM, respectively.

KH064 is a sPLA2-IIA inhibitor of oral activity.

SB-435495 hydrochloride，一种有效的、选择性的、可逆性非共价口服Lp-PLA2抑制剂，IC50值为0.06 nM。

MγLnFP, an analog of methyl arachidonyl fluozophosphonate (MAFP), holds significance in pharmacological research due to its potential as an inhibitor of phospholipases, FAAH, and its role as a CB receptor ligand. However, the properties and effects of the γ-linolenyl variant of MAFP remain to be fully explored.

A3373 是新型 PLD1 和 PLD2 抑制剂，对 PLD1 的 IC50 为 325 nM ，对 PLD2 的 IC50 为 15.15 µM，能够有效抑制 LPS 诱导的免疫反应，并在自身免疫性关节炎、骨脱矿及破骨细胞生成等方面发挥关键作用。